Cardiovascular Risk Factor Clinical Trial
Official title:
Personal Lifestyle Engine (PLX) is an Employee Wellness Platform and App Used at the Personal Lifestyle Medicine Center (PLMC). This Study Examines Correlations Between Lifestyle Factors, Genomic Data, Physical Exam Finding and Biomarkers
NCT number | NCT04007939 |
Other study ID # | PLX-PLMC |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2018 |
Est. completion date | December 31, 2022 |
Verified date | October 2023 |
Source | Metagenics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory. Technology has provided the tools to collect data in ways not previously possible. Individuals can now collect information on their genome (including their genetic predisposition to tolerate medications and to respond to healthy lifestyle programs) that will modify their lifestyle and therapeutic choices. Beyond spot checks of vital signs and weight, individuals can now collect information on body composition, continuous monitoring of heart rate, blood pressure, and even blood sugar. Data on food consumption at a caloric, macronutrient and even micronutrient level can be collected. Standard medical histories and detailed physical examination findings and laboratory biomarkers can be correlated with this data. Collections of individual patient data will need to be managed through computer programs and smart phone applications that provide direct feedback about the influence of lifestyle on health, wellness and biomarkers. To this end, Metagenics is designing and is launching a smart phone application, Personal Lifestyle Engine (PLX), for individual use by patients and their healthcare providers. The statistical analysis of these data is the primary objective of this study.
Status | Completed |
Enrollment | 400 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Male or Female - Ages 18-80, inclusive - Willing to give written informed consent to participate in the study Exclusion Criteria: - A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease. - Known infection with human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B or C. - Inability to comply with study and/or follow-up visits. - Any concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the Principle Investigator (PI), would preclude safe participation in this study or interfere with compliance. - Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance. |
Country | Name | City | State |
---|---|---|---|
United States | Personalized Lifestyle Medicine Center | Gig Harbor | Washington |
Lead Sponsor | Collaborator |
---|---|
Metagenics, Inc. | MetaProteomics LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Height | measured in meter (m) | Baseline | |
Primary | Weight | measured in kilogram (kg) | Baseline | |
Primary | Body Mass index (BMI) | BMI is measured in (weight in kilogram (kg)/ height in meter (m)^2) outcome in double digits. | Baseline | |
Primary | Waist Circumference (WC) | measured in centimeters (cm) | Baseline | |
Primary | Hip Circumference (HC) | measured in cm | Baseline | |
Primary | Waist-to-Hip Ratio (WHR) | WHR is numerical (0.00) and is and indicator for major health risk. | Baseline | |
Primary | Glucose | Fasting glucose levels measured in blood in milligram/deciLiter (mg/dL) | Baseline | |
Primary | Total Cholesterol | Fasting total cholesterol level is measured in serum in mg/dL | Baseline | |
Primary | Anti-Nuclear Antibodies (ANA) | ANA is measured as a titer by serum dilution detects autoimmune disease. | Baseline | |
Primary | 25-hydroxy (OH) Vitamin D3 | 25-OH vitamin D3 is measured in blood in nanogram/milliLiter (ng/mL) and detects deficiencies. | Baseline | |
Primary | High sensitivity C-Reactive Protein (Hs-CRP) | Hs-CRP is measured in blood in mg/L detects inflammation. | Baseline | |
Primary | Homocysteine | Homocysteine is measured in serum in micromol/Liter (µmol/L) | Baseline | |
Primary | Omega-3 Fatty Acids | Omega-3 fatty acids: Eicosapentaenoic (EPA), Docosahexaenoic (DHA), and Docosapentaenoic (DPA) levels are measured in % weight. | Baseline | |
Primary | Beck Depression Inventory (BDI) | BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Rating system: 1-10: These ups and downs are considered normal; 11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Severe depression; over 40: Extreme depression | Baseline | |
Primary | Beck Anxiety Inventory (BAI) | BAI is a multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults.The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. The standardized cutoffs[4] are:
0-7: minimal anxiety 8-15: mild anxiety 16-25: moderate anxiety 26-63: severe anxiety |
Baseline | |
Primary | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Test | PROMIS Sleep Disturbance Test is a self-scored test to identify sleep disturbance. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe | Baseline | |
Primary | Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Test | PROMIS Anxiety test is a 7-item questionnaire that assesses the pure domain of anxiety in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe | Baseline | |
Primary | Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form (SF) | PROMIS Depression SF is an 8-item questionnaire that assesses the pure domain of depression in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe | Baseline | |
Primary | Genomics | DNA polymorphism measured using 23&Me | Baseline | |
Primary | Stool | Stool analysis measured by a stool analysis kit from American Gut | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04481503 -
Transthoracic Echocardiography of Ventricular Function of Parturients in Labor
|
||
Terminated |
NCT04088240 -
Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease
|
N/A | |
Completed |
NCT03410342 -
The Effects of Types of Fruits and Vegetables on Vascular Function
|
N/A | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Recruiting |
NCT04231838 -
Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04562467 -
The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
|
Phase 4 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Completed |
NCT04551872 -
RESILIENCE: Personalizing Cardiovascular Health
|
N/A | |
Enrolling by invitation |
NCT03314818 -
Natural History of Carotid Plaque as Determined by 3D Ultrasound
|
N/A | |
Completed |
NCT03060811 -
Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults
|
N/A | |
Completed |
NCT04279704 -
Overcoming Obstacles in Epigenetic Analysis of Human Twins
|
||
Completed |
NCT01050205 -
The Healthy Lifestyle Project
|
N/A | |
Completed |
NCT03570840 -
Pediatric Metabolic Syndrome Study
|
||
Completed |
NCT03039023 -
Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans
|
N/A | |
Completed |
NCT03646175 -
Choline Supplementation and Cardiovascular Health
|
N/A |